Kornimate/medical-research-clean huggingface dataset:
study in patients with unresectable and metastatic melanoma: the optimize study

Conditions: Melanoma

Summary: this study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma. the dosing, duration, regimen, indication, and treatments will be observed. the survival rate of these patients will also be observed.

this is a non-interventional, observational study with the primary objective to assess and describe "real world" patterns of care in the treatment of patients with unresectable or metastatic melanoma. a sample size of 1,600 prospective patients will provide sufficient information to explore this primary objective. there will be no forced number of patients enrolled into a specific treatment cohort. setting or controlling specific treatment enrollment cohort counts would invalidate the results of the primary objective of the study. no primary hypothesis is being tested.

Eligibility criteria:
inclusion criteria: prospective cohort patients: * diagnosis date must occur on or after march 24, 2011 (date of ipilimumab approval in us) * diagnosis of stage iii (unresectable) or stage iv melanoma (includes mucosal, uveal acral-lentiginous, leptomeningeal disease) * age ≥ 18 years at time of entry into study * patients must be actively receiving or scheduled to receive systemic treatment (any line, eg, first, second, third line \[including investigational drugs\]). * for patients initiating new treatment, treatment must be started within 28 days after signing informed consent. * for patients currently receiving treatment, patients must enroll within the first 21 days of starting new treatment retrospective cohort patients: * patients with diagnosis of confirmed unresectable stage iii or stage iv melanoma (including mucosal, uveal, acral-lentiginous, leptomeningeal disease) * age ≥ 18 years at time of unresectable or metastatic melanoma diagnosis * initiated therapy for unresectable or metastatic melanoma within 4 years prior to approval of ipilimumab (first immune checkpoint inhibitor therapy approved in us) * march 25, 2007 - march 24, 2011 * one year of follow-up data is required from date of therapy initiation, if a patient passed away within the one year of follow-up; such patients are still eligible and the date of death will be collected. 1. if retrospective patients have at least one year of follow-up data and are then treated with immuno-oncology, immune checkpoint inhibitor therapy, or targeted therapy, these patients will be analyzed separately. exclusion criteria: prospective patients: * patients participating in a clinical study that does not allow enrollment into a non interventional study or clinical studies in which the investigational treatment is blinded * patients who started new treatment \> 21 days * patients who enrolled in study but did not initiate treatment before 28 days * patients with current malignancies (except non-melanoma skin cancer and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) that requires additional systemic therapy

Keywords: metastatic unresectable
surgical correction of cicatricial ectropion

Conditions: Patients With Cicatricial Ectropion; Over 18-year-old; With Complete Clinical Record

Summary: the main purpose of this study is to verify and compare the treatment effects of scarred ectropion surgery, perform statistical descriptions, compare patients undergoing tarsal strip and skin flap procedures with those undergoing simple skin flap treatment, and compare their pre- and post-operative ectropion grading scale (egs) and subjective and objective symptom changes. secondary objective: to observe the incidence and resolution of complications after lower eyelid ectropion surgery. compare postoperative effects among patients of different ages undergoing the same surgery.


Eligibility criteria:
inclusion criteria: * patients with cicatricial ectropion; * over 18-year-old; * with complete clinical record. exclusion criteria: * patients with severe complications
adjustable strabismus surgery

Conditions: Strabismus

Summary: strabismus, whether congenital or acquired, is a common visual and cosmetic problem, especially for the young. adjustable suture strabismus surgery is not in vogue in our country. this technique gives the surgeon a second attempt to provide a better outcome for the patients.


Eligibility criteria:
horizontal, vertical and complex strabismus cases (sensory, paralytic, nystagmus, monocular elevation deficit and dissociated vertical/horizontal deviation) were included, along with patients with a previous history of strabismus surgery. myasthenia gravis was excluded along with noncooperative children; less than 7 years of age. those who did not return for a one year follow up also had to be excluded.
minimally invasive surgery in treating patients with spinal tumors

Conditions: Adult Spinal Cord Neoplasm; Recurrent Adult Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Metastases

Summary: this randomized clinical trial studies minimally invasive surgery in treating patients with spinal tumors. posterior spinal tumor resection and anterior and posterior spinal tumor resection are less invasive types of surgery for spinal tumors and may have fewer side effects and improve recovery

primary objectives: i. length of operation (operating room \[or\] time). ii. estimated blood loss (ebl). iii. complication rate. iv. neurological preservation. secondary objectives: i. motor strength and sensory level (neurological outcome). ii. bladder and bowel function. iii. post-operative pain. iv. hospital length of stay (recovery time). v. arthrodesis. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients undergo posterior spinal tumor resection on day 0. arm ii: patients undergo anterior and posterior spinal tumor resection on day 0. after completion of study treatment, patients are followed up for 6 months.

Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of primary, secondary or metastatic spine tumor and be undergoing any posterior spinal fusion with or without anterior fusion anywhere from occiput to sacrum * greater than 3 month life expectancy * women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately * all subjects must have the ability to understand and the willingness to sign a written informed consent exclusion criteria: * patients who are not surgical candidates for spine tumor removal, determined by the surgical team * patients who have undergone previous spine surgery for tumor removal will be excluded * patients with renal cell carcinoma * as there is an emphasis on blood loss and length of surgery, the critical variable for homogeneity is the vascularity of the tumor; hypervascular spine tumors are regarded by surgeons as amongst the most challenging of cases; by far the three most common hypervascular metastatic tumors are those arising from renal cell carcinoma, thyroid carcinoma and melanoma; these pathologies are usually regarded as a distinct subset for this reason in the majority of studies; because we rarely encounter the later two pathologies in our practice, we chose to include only the former; however, to further homogenize our study population we will exclude all three of the known hypervascular metastatic spine tumors * subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
comparison of thrombgolytic and anticoagulation therapy in submassive pulmonary embolism

Conditions: Pulmonary Embolism

Summary: currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. the aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.

standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation therapy. in case of troponin positivity and/or echocardiographic findings as i.e. thrombi in rv thrombolytic therapy should be considered. the aim of this trial is to compare the two treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary hypertension, right ventricular failure, exercise capacity.

Eligibility criteria:
inclusion criteria: * moderate risk pulmonary embolism as defined by the european society of cardiology /esc/ guidelines * signed informed consent exclusion criteria: * patient not willing to sigh informed consent * absolute contraindication of thrombolysis * inability to obtain meaningfull echocardiographic images¨ * pulmonary arterial hypertension * known right ventricular failure

Keywords: moderate risk acute pulmonary embolism
evaluating auscul-x, a touch free digital stethoscope

Conditions: COVID-19

Summary: auscul-x a touch free digital stethoscope will permit physical distancing of healthcare providers while maintaining the ability to auscultate patients from a safe distance (over 10 feet away)

the auscul-x system (ausculsciences canada, inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect hcps from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). the sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. this practice of distancing in the workplace is a key cdc and phac recommendation to protect the frontline hcp from exposure risk to the highly contagious covid- 19 virus and other communicable diseases. the auscul-x not only has the potential to better protect hcps from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. in addition, the auscul-x allows multiple hcps to listen to the patient's heart and lung sounds simultaneously

Eligibility criteria:
inclusion criteria: * \>/=18 years old * admitted to iccu and csicu at uohi exclusion criteria: * age \< 18 years old * medically unstable * chest wall deformity or wounds in adhesive application areas * unwillingness or inability to provide informed consent or to comply with protocol
the effectiveness of two different types of shoulder slings in stroke

Conditions: Hemiplegia; Rehabilitation

Summary: the aim of this study is to investigate the effectiveness of shoulder slings on pain, motor function, daily life and balance in acute hemiplegic patients and to investigate whether different types of slings are superior to each other.

thirty-two patients with hemiplegic shoulder subluxation due to acute stroke were divided into two groups: shoulder supported slings and forearm supported slings. hemiplegia rehabilitation passive and active-assistive range of motion, stretching, and neurophysiologic exercises were performed for all patients per day for 8 weeks.pain assessment was performed with visual analog scale, sensorimotor evaluation was performed with fugl meyer assessment of motor function,daily life activities were assessed with barthel index, and balance was evaluated with berg balance scale.

Eligibility criteria:
inclusion criteria: * acute patients who were independent and ambulatory prior to stroke and had their first stroke attack (\<3 months) * mini-mental status test (mmst) score ≥ 24, * developing hemiplegia after stroke, standing independently for at least 2 minutes, * lower limb being in stage 4-5 according to the brunnstrom approach (for ambulation and standard balance) * upper limb being in stage 1-2 according to the brunnstrom approach * spasticity 0-1+ according to modified ashworth scale exclusion criteria: * has a neurological history other than the diagnosis of hemiplegia (parkinson's etc.) * having used shoulder slings and orthosis. * having a disease that can affect balance (cranial, etc.)

Keywords: stroke subluxation shoulder slings
use of human dehydrated amnion chorion allograft in closed hemorroidectomy

Conditions: External Hemorrhoid; External Hemorrhoid Thrombosed

Summary: the purpose of this study is to determine the safety and effectiveness of human dehydrated amnion chorion allograft in closed hemorrhoidectomy as assessed by patient and wound assessments.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of acutely thrombosed hemorrhoid or an external hemorrhoid exceeding 72 hours in duration 2. subject is undergoing closed hemorrhoidectomy as their definitive treatment for the grade 2-4 hemorrhoid 3. subject is age 18 or older 4. subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study exclusion criteria: 1. subject has a known history of poor compliance with medical treatments 2. subject has signs and symptoms of active cirrhosis 3. subject has signs and symptoms of crohn's disease complicated by perianal manifestations 4. subject is currently taking immunosuppressive medications 5. subject has had previous surgery in the target area within the past 6 months prior to treatment or plans to have surgery other than closed hemorrhoidectomy in the target area within 180 days of treatment 6. subject is currently receiving radiation therapy or chemotherapy 7. subject has used an investigational drug, device or biologic within 12 weeks prior to treatment 8. subject is pregnant at enrollment or is planning to become pregnant within 180 days of treatment; subject intends to breastfeed during the course of the trial 9. subject has any significant medical condition(s) that, in the opinion of the investigator, would interfere with protocol evaluation and participation 10. subject has an allergy or known sensitivity to aminoglycoside antibiotics such as gentamicin sulfate and/or streptomycin sulfate
steroid injection for the treatment of greater trochanteric pain syndrome

Conditions: Bursitis

Summary: the objective of this study is to conduct a randomized, single-blinded placebo controlled trial comparing two modalities for the treatment of pain and mobility associated with trochanteric bursitis: (1) injection of glucocorticosteroid and local anesthetic, (2) injection of local anesthetic. we hope to determine whether steroid injections provide a statistically significant improvement in pain symptoms and hip mobility in subjects with trochanteric bursitis, as compared to an injection of local anesthetic. our null hypothesis is that no statistically significant difference exists between the two treatment modalities.

trochanteric bursitis is an inflammation of the bursal sac overlying the greater trochanter of the femur. the etiology of this disease is unknown, but it is clinically characterized by chronic aching pain over the lateral aspect of the hip, which can be exacerbated by certain movements such as external rotation and abduction (2). in order to objectively determine the level of pain and mobility associated with trochanteric bursitis, some orthopaedic surgeons use scoring systems (a qualitative and quantitative scoring test) to assess patients (4). in our practice, trochanteric bursitis has been treated by injection of glucocorticosteroids (steroids) combined with local anesthetic at the site of the greater trochanter (1). additionally, it has been found that increasing steroid dosage provides a greater level of relief (3). although steroids are usually an effective treatment, no studies to date have compared steroid injections for relief of trochanteric bursitis pain and mobility versus a placebo injection or local anesthetic injection alone.

Eligibility criteria:
inclusion criteria: * adult patients with tenderness at the greater trochanter exclusion criteria: * subjects \< 17 years of age * subjects with previous surgery to the greater trochanter * subjects allergic to lidocaine, marcaine, or depomedrol
quality control of ce-certified phonak hearing aids - 2019_19

Conditions: Hearing Loss; Sensorineural Hearing Loss

Summary: phonak hearing systems pass through different development and study stages. at an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. if the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. afterwards, and prior to product launch, the phonak hearing systems undergo a final quality control in terms of clinical trials. this is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. this will be a clinical evaluation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

in this study one ce-labeled phonak behind-the-ear (bte) devices is investigated including ce-labeled compatible accessories. the experimental device will be investigated regarding its performance of speech understanding in noise with and without an accessory existing of an external microphone to pick sound at a certain target. a secondary objective of this study is the investigation of the overall system stability in daily life situations. the experimental device contains direct connectivity functionality. another objective of this study is the investigation of the subjective occlusion effect of different acoustic couplings. this will be a clinical evaluation which will be conducted mono centric at sonova ag headquarters based in stäfa (switzerland).

Eligibility criteria:
inclusion criteria: * adult hearing impaired persons (minimum age: 18 years, mild to moderate hearing loss) without hearing aid experience * good written and spoken (swiss) german language skills * healthy outer ear * ability to fill in a questionnaire (p/ecrf) conscientiously * informed consent as documented by signature * owning a compatible smartphone * hearing loss in range of n2-n3 (iso 60118-15) exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments in stäfa (switzerland) * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result * known psychological problems * central hearing disorders
evaluation of safety of pomalidomide in combination with dexamethasone (low dose) in patients with refractory or relapsed and refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary purpose of the study is to evaluate the safety and efficacy and to generate pk and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. the study consists of a screening phase within 28 days prior to cycle 1 day 1, a treatment phase and a follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years. in addition, the collection of steady-state pk data from a large population will enable robust population pk and assess pomalidomide exposure response analyses. the exploratory objectives of the study are to investigate potential markers predictive of pom response or resistance and pharmacodynamic markers.


Eligibility criteria:
inclusion criteria: * patients ≥18 years old, who must understand and voluntarily sign an informed consent. * patients must have documented diagnosis of multiple myeloma and have measurable disease. * patients must have undergone prior treatment with ≥ 2 treatments lines, of anti-myeloma therapy. * patients must have either refractory or relapsed and refractory disease. * patients must have received at least 2 consecutive cycles of prior treatment that include lenalidomide and bortezomib, either alone or in combination regimens. * patients must have received adequate alkylator therapy exclusion criteria: * prior history of malignancies, other than multiple myeloma. * previous therapy with pomalidomide, hypersensitivity to thalidomide and lenalidomide or dexamethasone. * patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant. * patients who are planning for or who are eligible for stem cell transplant. * patients who received major surgery and any anti-myeloma drug therapy within the last 14 days of starting study treatment. * patients with a current disease that can interfere with protocol procedures or study treatment. * patients unable or unwilling to undergo antithrombotic prophylactic treatment. * pregnant or breastfeeding females.

Keywords: multiple myeloma relapsed multiple myeloma relapsed and refractory multiple myeloma pomalidomide dexamethasone